Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City.

Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D.

J Urban Health. 2004 Mar;81(1):20-4.

2.

High hepatitis C incidence in new injecting drug users: a policy failure?

Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM.

Aust N Z J Public Health. 2007 Feb;31(1):30-5.

PMID:
17333606
3.

Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.

Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S11-9.

PMID:
9663618
4.

Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience.

Roy E, Boudreau JF, Boivin JF.

Drug Alcohol Depend. 2009 Jun 1;102(1-3):158-61. doi: 10.1016/j.drugalcdep.2009.01.006. Epub 2009 Feb 28.

PMID:
19251382
5.

HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway.

Miller M, Mella I, Moi H, Eskild A.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):373-9.

PMID:
12843749
6.

Injection of drug residue as a potential risk factor for HCV acquisition among Montréal young injection drug users.

Roy E, Arruda N, Leclerc P, Haley N, Bruneau J, Boivin JF.

Drug Alcohol Depend. 2012 Nov 1;126(1-2):246-50. doi: 10.1016/j.drugalcdep.2012.05.018. Epub 2012 Jun 13.

PMID:
22699096
7.

Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy.

Quaglio G, Lugoboni F, Pajusco B, Sarti M, Talamini G, Lechi A, Mezzelani P, Des Jarlais DC.

Clin Infect Dis. 2003 Jul 1;37(1):33-40. Epub 2003 Jun 24.

PMID:
12830406
8.

Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.

Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL.

Addiction. 2006 Oct;101(10):1499-508.

PMID:
16968352
9.

The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users.

Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D.

Addiction. 2012 Jul;107(7):1318-27. doi: 10.1111/j.1360-0443.2012.03803.x. Epub 2012 Mar 22.

PMID:
22248184
10.

High hepatitis C virus prevalence and incidence among Canadian intravenous drug users.

Roy E, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, Rochefort J, Claessens C; SurvUDI Working Group.

Int J STD AIDS. 2007 Jan;18(1):23-7.

PMID:
17326858
11.

Hepatitis C virus incidence among injecting drug users on opioid replacement therapy.

Hallinan R, Byrne A, Amin J, Dore GJ.

Aust N Z J Public Health. 2004 Dec;28(6):576-8.

PMID:
15707209
12.

Social circumstances of initiation of injection drug use and early shooting gallery attendance: implications for HIV intervention among adolescent and young adult injection drug users.

Fuller CM, Vlahov D, Latkin CA, Ompad DC, Celentano DD, Strathdee SA.

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):86-93.

PMID:
12514419
13.

Hepatitis C virus infection among a cohort of Victorian injecting drug users.

Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA.

Med J Aust. 1993 Aug 16;159(4):237-41.

PMID:
7692222
14.

Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis.

Xia X, Luo J, Bai J, Yu R.

Public Health. 2008 Oct;122(10):990-1003. doi: 10.1016/j.puhe.2008.01.014. Epub 2008 May 19. Review.

PMID:
18486955
15.

Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.

Wand H, Spiegelman D, Law M, Jalaludin B, Kaldor J, Maher L.

Addiction. 2009 Dec;104(12):2049-56. doi: 10.1111/j.1360-0443.2009.02704.x. Epub 2009 Oct 5.

PMID:
19804463
16.

Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994-6.

López-Zetina J, Ford W, Weber M, Barna S, Woerhle T, Kerndt P, Monterroso E.

Sex Transm Infect. 2000 Dec;76(6):462-9.

17.

Hepatitis C infection among drug users in northern Thailand.

Jittiwutikarn J, Thongsawat S, Suriyanon V, Maneekarn N, Celentano D, Razak MH, Srirak N, Vongchak T, Kawichai S, Thomas D, Sripaipan T, Netski D, Ananthakrishnan A, Nelson KE.

Am J Trop Med Hyg. 2006 Jun;74(6):1111-6.

PMID:
16760529
18.

Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City.

Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, Rockwell R, Hoover D, Williams IT, Monterroso ER.

Am J Public Health. 2001 Jan;91(1):23-30.

19.

Indications of immune protection from hepatitis C infection.

Aitken CK, Bowden S, Hellard M, Crofts N.

J Urban Health. 2004 Mar;81(1):58-60.

20.

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.

Miller CL, Johnston C, Spittal PM, Li K, Laliberté N, Montaner JS, Schechter MT.

Hepatology. 2002 Sep;36(3):737-42.

PMID:
12198668

Supplemental Content

Support Center